530 related articles for article (PubMed ID: 16861147)
1. Serotonergic mechanisms in amyotrophic lateral sclerosis.
Sandyk R
Int J Neurosci; 2006 Jul; 116(7):775-826. PubMed ID: 16861147
[TBL] [Abstract][Full Text] [Related]
2. Increased internalisation and degradation of GLT-1 glial glutamate transporter in a cell model for familial amyotrophic lateral sclerosis (ALS).
Vanoni C; Massari S; Losa M; Carrega P; Perego C; Conforti L; Pietrini G
J Cell Sci; 2004 Oct; 117(Pt 22):5417-26. PubMed ID: 15466883
[TBL] [Abstract][Full Text] [Related]
3. Early signs of motoneuron vulnerability in a disease model system: Characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice.
Avossa D; Grandolfo M; Mazzarol F; Zatta M; Ballerini L
Neuroscience; 2006; 138(4):1179-94. PubMed ID: 16442737
[TBL] [Abstract][Full Text] [Related]
4. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis.
Heath PR; Shaw PJ
Muscle Nerve; 2002 Oct; 26(4):438-58. PubMed ID: 12362409
[TBL] [Abstract][Full Text] [Related]
5. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis.
Rothstein JD
Clin Neurosci; 1995-1996; 3(6):348-59. PubMed ID: 9021256
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid from amyotrophic lateral sclerosis patients preferentially elevates intracellular calcium and toxicity in motor neurons via AMPA/kainate receptor.
Sen I; Nalini A; Joshi NB; Joshi PG
J Neurol Sci; 2005 Aug; 235(1-2):45-54. PubMed ID: 15936037
[TBL] [Abstract][Full Text] [Related]
7. Chronic elevation of extracellular glutamate due to transport blockade is innocuous for spinal motoneurons in vivo.
Tovar-Y-Romo LB; Santa-Cruz LD; Zepeda A; Tapia R
Neurochem Int; 2009; 54(3-4):186-91. PubMed ID: 19100799
[TBL] [Abstract][Full Text] [Related]
8. A systematic study of brainstem motor nuclei in a mouse model of ALS, the effects of lithium.
Ferrucci M; Spalloni A; Bartalucci A; Cantafora E; Fulceri F; Nutini M; Longone P; Paparelli A; Fornai F
Neurobiol Dis; 2010 Feb; 37(2):370-83. PubMed ID: 19874893
[TBL] [Abstract][Full Text] [Related]
9. Aberrant control of motoneuronal excitability in amyotrophic lateral sclerosis: excitatory glutamate/D-serine vs. inhibitory glycine/gamma-aminobutanoic acid (GABA).
Sasabe J; Aiso S
Chem Biodivers; 2010 Jun; 7(6):1479-90. PubMed ID: 20564566
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of metabotropic glutamate receptor inhibition on amyotrophic lateral sclerosis-cerebrospinal fluid toxicity in vitro.
Anneser JM; Chahli C; Borasio GD
Neuroscience; 2006 Sep; 141(4):1879-86. PubMed ID: 16820266
[TBL] [Abstract][Full Text] [Related]
11. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.
Rothstein JD
Adv Neurol; 1995; 68():7-20; discussion 21-7. PubMed ID: 8787245
[TBL] [Abstract][Full Text] [Related]
12. Riluzole is a potent drug to protect neonatal rat hypoglossal motoneurons in vitro from excitotoxicity due to glutamate uptake block.
Cifra A; Nani F; Nistri A
Eur J Neurosci; 2011 Mar; 33(5):899-913. PubMed ID: 21324003
[TBL] [Abstract][Full Text] [Related]
13. Altered in-vitro and in-vivo expression of glial glutamate transporter-1 following exposure to cerebrospinal fluid of amyotrophic lateral sclerosis patients.
Shobha K; Vijayalakshmi K; Alladi PA; Nalini A; Sathyaprabha TN; Raju TR
J Neurol Sci; 2007 Mar; 254(1-2):9-16. PubMed ID: 17254611
[TBL] [Abstract][Full Text] [Related]
14. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis.
Alexianu ME; Ho BK; Mohamed AH; La Bella V; Smith RG; Appel SH
Ann Neurol; 1994 Dec; 36(6):846-58. PubMed ID: 7998770
[TBL] [Abstract][Full Text] [Related]
15. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis.
Yoo YE; Ko CP
Exp Neurol; 2011 Sep; 231(1):147-59. PubMed ID: 21712032
[TBL] [Abstract][Full Text] [Related]
16. Substance P receptor activation induces downregulation of the AMPA receptor functionality in cortical neurons from a genetic model of Amyotrophic Lateral Sclerosis.
Caioli S; Curcio L; Pieri M; Antonini A; Marolda R; Severini C; Zona C
Neurobiol Dis; 2011 Oct; 44(1):92-101. PubMed ID: 21726643
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of GABAA and glycine receptors in ALS-resistant vs. ALS-vulnerable motoneurons: possible implications for selective vulnerability of motoneurons.
Lorenzo LE; Barbe A; Portalier P; Fritschy JM; Bras H
Eur J Neurosci; 2006 Jun; 23(12):3161-70. PubMed ID: 16820006
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase.
Tolosa L; Mir M; Asensio VJ; Olmos G; Lladó J
J Neurochem; 2008 May; 105(4):1080-90. PubMed ID: 18182045
[TBL] [Abstract][Full Text] [Related]
19. TNF-α potentiates glutamate-induced spinal cord motoneuron death via NF-κB.
Tolosa L; Caraballo-Miralles V; Olmos G; Lladó J
Mol Cell Neurosci; 2011 Jan; 46(1):176-86. PubMed ID: 20849956
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of group I metabotropic glutamate receptors in human motoneurons at low and high risk of degeneration in amyotrophic lateral sclerosis.
Ma L; Ostrovsky H; Miles G; Lipski J; Funk GD; Nicholson LF
Neuroscience; 2006 Nov; 143(1):95-104. PubMed ID: 16979830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
